# Editas Medicine

> Gene editing treatments development

Business model and tags: B2B, Has physical offices, Publicly traded, Pharma & life sciences, Has in-house R&D

## About Editas Medicine

A clinical stage genome editing company focused on using CRISPR technology to develop transformative treatments for serious diseases worldwide

## Key facts

- **Industry**: Biotechnology Research
- **Company size**: 51–250 employees
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2013
- **Revenue**: $40.5M (FY2025, publicly reported)
- **Website**: [editasmedicine.com](https://www.editasmedicine.com/)
- **LinkedIn**: [linkedin.com/company/editas-medicine](https://www.linkedin.com/company/editas-medicine)

## Editas Medicine at a glance

Editas Medicine is a B2B company in the Biotechnology Research industry, headquartered in Cambridge, Massachusetts, United States.

Editas Medicine was founded in 2013.

Editas Medicine has 51–250 employees.

Editas Medicine's revenue is $40.5M (FY2025, publicly reported).

## Frequently asked questions about Editas Medicine

### What is Editas Medicine's revenue?

Editas Medicine's revenue is $40.5M (FY2025, publicly reported).

### How many employees does Editas Medicine have?

Editas Medicine has 51–250 employees.

### Where is Editas Medicine headquartered?

Editas Medicine is headquartered in Cambridge, Massachusetts, United States.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/editas-medicine
